Blood Disorders & Hematology Clinical Trials Update: Week 24, 2026

Published June 12, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Antibody + Chemotherapy in Follicular Lymphoma FLIPI2-5

This phase III clinical trial is testing a new combination of mosunetuzumab, an immune therapy, with lenalidomide against the current standard treatment of antibody plus chemotherapy for patients with follicular lymphoma. If successful, this new approach could provide an effective treatment option that works differently and may have a different side effect profile compared to traditional chemotherapy. The study is enrolling patients worldwide and aims to improve care for those newly diagnosed with this type of lymphoma.

Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies

This ongoing phase III study follows patients who have received Galapagos CAR T-cell therapy for blood cancers to better understand the long-term safety and benefits of this gene therapy. CAR T-cell treatments have shown promise in targeting cancer cells by reprogramming the patient’s own immune system. Tracking patients for up to 15 years will provide valuable information about lasting effects and help guide future use of this technology.

TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma

This phase III trial is testing TR115, a new drug that targets a specific protein involved in cancer growth, in patients with peripheral T-cell or natural killer (NK) cell lymphoma who have relapsed or not responded to prior treatments. If TR115 proves more effective than existing therapies, it could offer a new option to improve survival and quality of life for these patients. The study is actively recruiting in China and expects to enroll around 180 participants.

Iberdomide Maintenance Therapy in Patients With Multiple Myeloma

This phase II study evaluates iberdomide as a maintenance treatment for patients with multiple myeloma following stem cell transplantation. Maintenance therapy aims to keep the cancer under control and delay relapse. Iberdomide may offer benefits such as fewer side effects or better tolerance compared to current standard maintenance drugs. The trial is recruiting in the United States and will monitor patients for at least a year to assess safety and effectiveness.

CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

This phase I trial investigates a novel gene therapy using CD30 CAR T cells in patients with relapsed Hodgkin’s or Non-Hodgkin lymphoma. The therapy involves modifying a patient’s immune cells to better recognize and attack lymphoma cells expressing the CD30 protein. This approach may improve treatment options for patients who have already undergone chemotherapy but still have active disease. The trial is recruiting in the United States and includes patients with prior treatments.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.